SCHEMBL32667653

SCHEMBL32667653

c1csc(-c2ccc(CN3CCNCC3)s2)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.55
LTA4H P09960 1/20 0.51
DPP4 P27487 4/20 0.50
HTT P42858 1/20 0.43
SIGMAR1 Q99720 1/20 0.42
ADORA2A P29274 2/20 0.39
DRD4 P21917 1/20 0.39
DRD3 P35462 1/20 0.39
LMNA P02545 2/20 0.39
MEN1 O00255 1/20 0.39
USP2 O75604 1/20 0.39
TP53 P04637 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CASP1 P29466 1/20 0.39
CYP2C19 P33261 1/20 0.39
BLM P54132 1/20 0.39
CASP7 P55210 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2026093 0.79 HTT (0.66) ALDH1A1HTTSIGMAR1DRD4DRD3
SCHEMBL12420819 0.79 ALDH1A1 (0.58) ALDH1A1SIGMAR1LMNACYP3A4CYP2C9
Hydrochloric Acid SCHEMBL2197173 0.78 ALDH1A1 (0.56) ALDH1A1SIGMAR1LMNACYP3A4CYP2C9
SCHEMBL32667767 0.75 ALDH1A1 (0.54) ALDH1A1SIGMAR1ADORA2ALMNAMEN1
SCHEMBL32667704 0.75 SIGMAR1 (0.56) LTA4HSIGMAR1MEN1CYP2C19BLM
SCHEMBL30790557 0.74 ALDH1A1 (0.47) ALDH1A1HTTSIGMAR1LMNAMEN1
SCHEMBL32667411 0.73 ALDH1A1 (0.55) ALDH1A1SIGMAR1MEN1BLMKMT2A
SCHEMBL29060004 0.72 LTA4H (0.53) ALDH1A1LTA4HDPP4LMNAMEN1
SCHEMBL21823759 0.71 LTA4H (0.71) ALDH1A1LTA4HDPP4HTTLMNA
SCHEMBL32667410 0.71 DRD2 (0.55) SIGMAR1DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028326-A1 COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF GLUETACS THERAPEUTICS SHANGHAI CO LTD (CN) 2026-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260028326-A1 COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF CDR2, CYC1, CLN6 ALDH1A1 527/4885LTA4H 2170/4885DPP4 4521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.